{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibjvdxppdx42p2wghc76qmpifoddnes2kaash5sx4avjwvwbbwp54",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mjeim4virtt2"
  },
  "path": "/2026/04/13/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain/",
  "publishedAt": "2026-04-13T06:24:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "BEIJING, April 13, 2026 /PRNewswire/ — On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of […]",
  "title": "Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain"
}